How to B(e)-1 Important Cell During Leishmania Infection
B-1 cells are an innate-like population of B lymphocytes that are subdivided into B-1a and B-1b distinguished by the presence or absence of CD5, respectively. B-1 cells can act as regulatory B cells, are able to present antigen and produce IL-10. Leishmaniasis in humans is a complex of diseases caus...
Saved in:
Published in | Frontiers in cellular and infection microbiology Vol. 9; p. 424 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
Switzerland
Frontiers Media S.A
14.01.2020
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | B-1 cells are an innate-like population of B lymphocytes that are subdivided into B-1a and B-1b distinguished by the presence or absence of CD5, respectively. B-1 cells can act as regulatory B cells, are able to present antigen and produce IL-10. Leishmaniasis in humans is a complex of diseases caused by parasites of the genus
. More than 20 species can infect humans, with each species causing the development of different immunological responses in the host. Susceptibility is usually related to the production of anti-inflammatory cytokines while the production of Th1 cytokines is indicative of resistance. However, few studies have attempted to evaluate the role of B-1 cells during either the
infection or
interaction with
parasites.
studies were performed using XID mice model, BALB/Xid mice have a mutation in the Bruton's tyrosine kinase, which is an important enzyme for developing B-1 and maturing B-2 lymphocytes leading to the presence of immature B-2 cells. Here, we compile these studies and assess the influence of B-1 cells on disease progression with different
species. |
---|---|
Bibliography: | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Review-1 This article was submitted to Parasite and Host, a section of the journal Frontiers in Cellular and Infection Microbiology Reviewed by: Hira Nakhasi, Center for Biologics Evaluation and Research (FDA), United States; Salvador Iborra, Complutense University of Madrid, Spain; Angamuthu Selvapandiyan, Jamia Hamdard University, India Edited by: Javier Moreno, Carlos III Health Institute, Spain |
ISSN: | 2235-2988 2235-2988 |
DOI: | 10.3389/fcimb.2019.00424 |